Literature DB >> 19533647

Diagnostic criteria for late-onset (childhood and adult) Pompe disease.

.   

Abstract

The diagnosis of late-onset (childhood and adult) Pompe disease can often be challenging, as it is a rare disease and the heterogeneous clinical presentation can mimic the presentation of other neuromuscular disorders. The objective was to develop a consensus-based algorithm for the diagnosis of late-onset Pompe disease. A systematic literature search was conducted, and an expert panel composed of neuromuscular specialists and individuals with expertise in Pompe disease reviewed the literature and convened for consensus development. An algorithm for the diagnosis of late-onset Pompe disease was created. Patients presenting with either a limb-girdle syndrome or dyspnea secondary to diaphragm weakness should undergo further testing, including evaluations of muscle strength, motor function, and pulmonary function. A blood-based acid alpha-glucosidase (GAA) enzyme activity assay is the recommended tool to screen for GAA enzyme deficiency. The diagnosis should be confirmed by a second test: either a second GAA enzyme activity assay in another tissue or GAA gene sequencing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533647     DOI: 10.1002/mus.21393

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

1.  Qualitative and quantitative skeletal muscle ultrasound in late-onset acid maltase deficiency.

Authors:  Craig M Zaidman; Elizabeth C Malkus; Catherine Siener; Julaine Florence; Alan Pestronk; Muhammad Al-Lozi
Journal:  Muscle Nerve       Date:  2011-07-13       Impact factor: 3.217

2.  Adult onset Pompe disease associated with multiple sclerosis.

Authors:  Maria Sepulveda; Elvira Munteis; Miguel A Rubio; Jordi Pascual; Jaume Roquer
Journal:  J Neurol       Date:  2011-05-26       Impact factor: 4.849

3.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Authors:  Adrian G Todd; Jessica A McElroy; Robert W Grange; David D Fuller; Glenn A Walter; Barry J Byrne; Darin J Falk
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

4.  Diaphragm Pacing as a Rehabilitative Tool for Patients With Pompe Disease Who Are Ventilator-Dependent: Case Series.

Authors:  Barbara K Smith; David D Fuller; A Daniel Martin; Lawrence Lottenberg; Saleem Islam; Lee Ann Lawson; Raymond P Onders; Barry J Byrne
Journal:  Phys Ther       Date:  2016-02-18

5.  Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.

Authors:  Thomas Hundsberger; Marianne Rohrbach; Lukas Kern; Kai M Rösler
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

Review 6.  Consensus treatment recommendations for late-onset Pompe disease.

Authors:  Edward J Cupler; Kenneth I Berger; Robert T Leshner; Gil I Wolfe; Jay J Han; Richard J Barohn; John T Kissel
Journal:  Muscle Nerve       Date:  2011-12-15       Impact factor: 3.217

Review 7.  Pompe disease: literature review and case series.

Authors:  Majed Dasouki; Omar Jawdat; Osama Almadhoun; Mamatha Pasnoor; April L McVey; Ahmad Abuzinadah; Laura Herbelin; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

8.  The brain in late-onset glycogenosis II: a structural and functional MRI study.

Authors:  Barbara Borroni; M S Cotelli; E Premi; S Gazzina; M Cosseddu; A Formenti; R Gasparotti; M Filosto; A Padovani
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

9.  Cough Effectiveness and Pulmonary Hygiene Practices in Patients with Pompe Disease.

Authors:  Teresa Pitts; Rachel Bordelon; Alyssa Huff; Barry J Byrne; Barbara K Smith
Journal:  Lung       Date:  2018-10-25       Impact factor: 2.584

10.  The emerging phenotype of long-term survivors with infantile Pompe disease.

Authors:  Sean N Prater; Suhrad G Banugaria; Stephanie M DeArmey; Eleanor G Botha; Erin M Stege; Laura E Case; Harrison N Jones; Chanika Phornphutkul; Raymond Y Wang; Sarah P Young; Priya S Kishnani
Journal:  Genet Med       Date:  2012-04-26       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.